Abcellera Biologics Inc ABCL

$13.38 +0.55 (4.29%)

Valuation

Market cap
3,624,142,000
Revenue TTM
$75,130,000
Net income TTM
$-146,410,000
PE ratio
0.00
Forward PE
—
Profit margin
-194.88%
Debt to equity
0.00

Trading

Volume
1,721,812
Avg volume
5,072,906
Day's range
$12.65 – $13.57
Shares out
306,611,000
Stochastic %K
97%
Beta
1.41
Analysts
Strong Sell
Price target
$16.82

Price

Company profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-medi...

Show more

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 559 9005
Website
https://www.abcellera.com
Address
150 W 4th Avenue, Vancouver, Canada

Latest news

Stocktwits

TradeWinner Oct 28, 4:48 PM
$ABCL assuming a few small sales before the fed. We fly afterwards and into the Nov 9 earnings which is two day before conferences. New info would be great at earnings to share at the conferences as well. That’s my thesis. 🤞🤞
0 replies
Stocktradesmoon Oct 28, 4:25 PM
$ABCL $14 UP Next!!
0 replies
Stocktradesmoon Oct 28, 4:18 PM
$ABCL
0 replies
Stocktradesmoon Oct 28, 4:17 PM
$ABCL
0 replies
Stocktradesmoon Oct 28, 4:16 PM
$ABCL
0 replies
Stocktradesmoon Oct 28, 3:41 PM
$ABCL ABcellera 🔥!!!
0 replies
teevee Oct 28, 3:23 PM
$ABCL
1 replies
PLTRLONGDONG Oct 28, 3:02 PM
$ABCL we will get the 2.61 fib at $26.71
0 replies